Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepa

24 Feb 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 24 Feb 2026. The item focuses on Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. Review the original article for the full source wording and details.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 24 Feb 2026.

The item focuses on Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Specialty

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Oncology • 20 May 2026

Br J CancerRelated by Specialty

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

Nat Rev OncRelated by Specialty

Source

Journal of Clinical Oncology (JCO)

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepa

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Autonomous pathology research using agentic AI shows potential in oncology

CCNE1 Gain Defines a Therapy-Refractory Gastric Cancer Subtype